Table 2.

Association between baseline orthostatic hypertension and clinical outcomes, stratified by blood pressure treatment group.

Outcomes	Intensive treatment group						Standard treatment group						Interaction p-value
	No orthostatic hypertension		Orthostatic hypertension		HR² (95% CI³)	p- value	No orthostatic hypertension		Orthostatic hypertension		HR² (95% CI³)	p- value
	n	Event rate¹	n	Event rate¹	HR² (95% CI³)	p- value	n	Event rate¹	n	Event rate¹	HR² (95% CI³)	p- value
Primary outcome	236	1.74	77	2.17	1.44 (1.10-1.87)	0.007	333	2.50	77	2.11	0.90 (0.70-1.16)	0.41	0.01
Components of primary outcome
Myocardial infarction	94	0.68	20	0.55	0.97 (0.60-1.57)	0.90	128	0.95	32	0.86	0.99 (0.67-1.47)	0.98	0.94
Acute coronary syndrome	37	0.27	8	0.22	1.03 (0.48-2.22)	0.95	38	0.28	9	0.24	0.96 (0.46-1.99)	0.90	0.89
Stroke	58	0.42	19	0.53	1.37 (0.80-2.33)	0.25	74	0.54	19	0.51	0.98 (0.59-1.62)	0.93	0.37
Heart failure	70	0.51	27	0.75	1.85 (1.17-2.94)	0.009	93	0.68	20	0.53	0.87 (0.53-1.42)	0.58	0.03
Cardiovascular disease death	36	0.26	19	0.52	2.59 (1.46-4.62)	0.001	72	0.52	15	0.40	0.84 (0.47-1.50)	0.56	0.07

All Cause Mortality	170	1.22	55	1.51	1.48 (1.08-2.01)	0.01	218	1.58	56	1.48	1.01 (0.75-1.36)	0.96	0.08

Kidney outcome (In participants without CKD at baseline)	127	1.33	31	1.17	0.91 (0.60-1.37)	0.64	37	0.38	10	0.36	0.93 (0.46-1.88)	0.84	0.95
Kidney outcome (In participants with CKD at baseline)	13	0.32	4	0.45	1.80 (0.57-5.72)	0.32	18	0.46	1	0.10	0.41 (0.05-3.63)	0.43	0.24

^1.

Events rates are measured as % per year

^2.

HR: Hazards ratio for orthostatic hypertension, compared to no orthostatic hypertension, CI: Confidence interval

^3.

Adjusting gender, race, smoking status, history of cardiovascular disease history, age, statin use, number of antihypertensive drugs, chronic kidney disease, body mass index, baseline seated systolic blood pressures, baseline total and HDL cholesterol, glomerular filtration rate and urine albumin/creatinine ratio